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The innate immune system is composed of a diverse set of host defense molecules, physi-
cal barriers, and specialized leukocytes and is the primary form of immune defense against
environmental insults. Another crucial role of innate immunity is to shape the long-lived
adaptive immune response mediated by T and B lymphocytes. The activation of pattern
recognition receptors (PRRs) from the Toll-like receptor family is now a classic example
of innate immune molecules influencing adaptive immunity, resulting in effective antigen
presentation to naïve T cells. More recent work suggests that the activation of another
family of PRRs, the NOD-like receptors (NLRs), induces a different set of innate immune
responses and accordingly, drives different aspects of adaptive immunity. Yet how this
unusually diverse family of molecules (some without canonical PRR function) regulates
immunity remains incompletely understood. In this review, we discuss the evidence for
and against NLR activity orchestrating adaptive immune responses during infectious as
well as non-infectious challenges.
Keywords: NLR, dendritic cell, NLRP3 inflammasome, NLRP10, vaccine response, autoimmunity, Th2 response,
asthma
INTRODUCTION
When pathogens or injuries threaten the body, two different
branches of the immune system work together to restore home-
ostasis: the innate and adaptive immune systems. They monitor
the tissues of vertebrates and use different tactics to recognize
and overcome threats. These two branches are inherently differ-
ent in the sensors and mechanisms employed in order to pro-
vide either immediate protection with broad specificity (innate
immunity) or delayed and prolonged protection with exquisite
specificity (adaptive immunity). Further, the two branches must
effectively coordinate a response in order to prevent excessive or
inappropriately targeted inflammation. As Charles Janeway wrote
in 1992, “the immune system evolved to discriminate infectious
non-self from non-infectious self” (1). We will use this para-
digm to develop a broadened classification system of five adaptive
immune response types and then review how nucleotide-binding
oligomerization domain-containing receptors (NOD-like recep-
tors or NLRs) potentially regulate the response to each. These five
categories are based on the origin of the target antigen affected
by the adaptive immune response: (1) foreign pathogenic targets
(i.e., antimicrobial immunity); (2) foreign non-pathogenic targets
(i.e., allergies); (3) self targets (i.e., autoimmunity); (4) altered self
targets (i.e., tumor immunity); and (5) foreign self targets (i.e.,
commensal homeostasis). The role of NLRs in each category is
likely different, as the initiation of immunity as well as the outcome
for the host are different (e.g., beneficial protection to pathogens
versus loss of tolerance resulting in self-destruction).
PATTERN RECOGNITION RECEPTORS IN INNATE AND ADAPTIVE
IMMUNITY
The innate immune system consists of barriers, networks of sol-
uble mediators, and myeloid-derived executioner (effector) cells
including macrophages, dendritic cells (DCs), and granulocytes.
It utilizes evolutionary conserved receptors to survey the extra-
cellular and intracellular environment for pathogenic elements
and injury. These molecules include pattern recognition recep-
tors (PRRs) and as the name suggests, they are able to recognize a
variety of common molecular motifs called “pathogen/microbe
associated molecular patterns” (PAMPs/MAMPs) derived from
microbes, and “damage associated molecular patterns” (DAMPs)
derived from mislocalized or damaged host molecules during
states of cell stress (2). PRRs exist in transmembrane, secreted,
and cytosolic forms. Toll-like receptors (TLRs) are located on the
cell surface and in endosomal compartments where they can rec-
ognize extracellular or phagocytosed pathogens (3). C-type lectin
receptors (CLRs) can be found in both membrane-bound and
secreted forms, and bind carbohydrate-based PAMPs and DAMPs
(4). RIG-I-like receptors (RLRs), AIM2-like receptors (ALRs), and
other nucleic acid sensing PRRs along with NLRs are located exclu-
sively in the cytosol and nucleus, where they detect pathogens or
processes that breach the cell membrane (2, 5–7). NLRs respond
to a wide variety of PAMPs and DAMPs as well as intracellular
and extracellular signals generated by other arms of the innate
and adaptive immune system. Following PRR activation, various
signaling cascades are induced that initiate or shape the appro-
priate inflammatory response and, mostly through the action of
DCs, activate T and B lymphocytes of the adaptive branch of the
immune system. As the highly specific antigen receptors on lym-
phocytes can sense an almost infinite diversity of antigens, a crucial
distinction between an“appropriate”and an“inappropriate”target
for the adaptive immune response is made during this step.
NLR FAMILY ARCHITECTURE AND FUNCTIONS
The array of cellular responses regulated by NLRs is striking
and includes transcription (e.g., of MHC molecules), enzymatic
activity (e.g., of caspases), and positive and negative regulation of
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FIGURE 1 | Functional categories of NLRs based on their roles in
shaping immune responses. Some NLRs have been found to play primary
roles in regulating particular pathways (e.g., transcription) or signaling
cascades (“signaling NLRs”) such as NOD1, NOD2, NLRP10 (putative
signaling NLR), and CIITA. Others regulate the formation of inflammasomes
(“inflammasome NLRs”) such as NLRP3 and NLRC4. Some do both such
as NLRP1, NLRC5, NLRP6, and NLRP12. The immune consequences of
these broad categories can be quite different. Although IL-1β and IL-18
derived from inflammasome activity can regulate particular aspects of
adaptive immunity, direct roles of each of these cytokines in promoting
non-lymphocyte based inflammatory reactions or commensal flora in the
gut have also been identified. The latter has been implicated in shaping the
adaptive immune system and therefore we linked these two categories;
however, no direct role has yet been identified for an NLR in this link. On
the other hand, NLRs involved in signaling cascades that in particular effect
dendritic cell function as antigen presenting cells have a more obvious
direct effect on adaptive immunity. IBD, inflammatory bowel disease;
NAFLD, non-alcoholic fatty liver disease.
intracellular signaling cascades (e.g., NF-κB pathway) (Figure 1).
This latter category of signaling NLRs primarily modulates path-
ways relevant to the innate immune response or its regulation of
adaptive immunity. Signaling through NOD1 and NOD2, after
sensing various bacterial peptidoglycan fragments, results in the
activation of pro-inflammatory NF-κB and MAPK pathways, and
the induction of autophagy (8–11). Extensive work on the bio-
chemistry, ligands, and role of NOD1 and NOD2 in the innate
and adaptive immune response has been done and is the topic of
an accompanying review by Boyle et al. (12). NLRP10 and NLRP12
are required for the migration of antigen presenting cells (APCs)
and thus have a role in defining the onset of adaptive immunity as
will be discussed further in subsequent sections (13, 14). The NLRs
CIITA and NLRC5 are induced by cytokines and act as transcrip-
tional activators of MHC molecules, thereby potently regulating
adaptive immunity. CIITA controls the transcription of MHC class
II molecules and related proteins necessary for the presentation of
antigen to CD4+ T cells; NLRC5 does the same for MHC class
I molecules and related proteins (15, 16) although it appears to
have a broader function in pathogen sensing as well (17–19). In
addition, several NLRs appear to have functions unrelated to the
recognition of pathogens or damage, such as tissue homeostasis
and embryonic development; however, further research is needed
to unravel their exact roles (20).
Some NLRs perform more than one of these functions and for
a majority of NLRs no known function has yet been identified.
Therefore NLRs are classified by their structure, which consists of
three distinct parts: a central nucleotide-binding domain (NBD),
a carboxy-terminal leucine-rich repeats (LRR), and an amino-
terminal effector domain. The effector domain instigates activity
and divides NLRs into four subfamilies: the NLRA family, with
an acidic domain, the NLRB family, with a baculoviral inhibitory
repeat (BIR) domain, the NLRC family, containing a caspase acti-
vation and recruitment domain (CARD) and the NLRP family,
which has a pyrin domain. Only NLRP1 and NLRP10 do not
have this basic structure (21, 22). The only domain common to
all NLRs is the central NBD, which has ATPase activity and is
thought to induce oligomerization of the NLR proteins following
activation (5).
NLR ACTIVATION
The classic paradigm for the function of a pattern recognition
receptor was established through the study of TLRs. TLRs sense
a foreign motif (e.g., a PAMP) on a pathogen through recep-
tor ligation of the LRR domain, resulting in the induction of an
inflammatory response and enhanced antigen presentation to lym-
phocytes [reviewed in Ref. (6)]; however, this paradigm does not
fit the NLRs. Except for a few members like NOD1, NOD2, and
NAIP5 (23–27), there is limited direct evidence that the LRR actu-
ally recognizes their respective agonists (28). It has been difficult
to precisely define how NLRs bind ligands, activate, and oligomer-
ize, although from electron microscopy data, a wheel-like structure
analogous to many of the other oligomerized STAND (signal trans-
duction ATPases with numerous domains) proteins appears to
form (29–31). A recent crystal structure of part of NLRC4 in the
inactive state suggests that the activity of this NLR is indeed regu-
lated by the LRR domain along with the adjacent helical domain
HD2 (32). Yet it had been previously demonstrated that instead
of directly interacting with its ligands, NLRC4 senses PAMPs with
the help of adaptor NLRs NAIP2 and NAIP5, which associate with
PrgJ and flagellin of flagellated bacteria, respectively, and control
the oligomerization of NLRC4 after ligand binding (25, 33).
Despite the many known stimuli, including insoluble crys-
tals, bacterial toxins, and extracellular ATP, the mechanism by
which NLRP3 is activated is only recently becoming clear. Because
of the diversity of these ligands, it is likely that they activate
NLRP3 through a shared mechanism involving desequestration
of a host-derived trigger (34, 35). Sensing of increased cytoso-
lic reactive oxygen species (ROS), intracellular calcium fluxes
(36–38), potassium efflux (39–42), protein kinase (PKR) bind-
ing (43), or the release of contents from phagolysosomes have
all been proposed as mechanisms. Numerous recent studies have
honed in on mitochondrial-derived triggers regulating the cellular
processes listed above or release of NLRP3 ligands from mito-
chondria including ATP, DNA, ROS, or mitochondria-associated
adaptor molecule (MAVS) (38, 44–51). Given the importance of
the mitochondria in regulating cell death, the potential trigger-
ing of NLPR3 activity by mitochondrial-derived signals suggests
an interesting and central role for this organelle in integrating
numerous cellular insults into a set of cell fate outcomes, some
of which might be NLR-dependent (52). Biochemical identifica-
tion of NLRP3 and other NLR-specific ligands, whether PAMPS,
DAMPS, or more traditional signaling pathway molecules, will
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greatly facilitate our understanding of how NLRs shape both
innate and adaptive immunity.
INFLAMMASOME COMPLEXES
After recognition of a PAMP or DAMP, a number of NLRs
(NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4, NLRC5,
NAIP2, NAIP5) form multi-protein complexes called inflam-
masomes (19, 33, 53–56). The signature events of a functional
inflammasome are the activation of caspase-1 and subsequent
cleavage of the pro-inflammatory cytokines IL-1β and IL-18 into
their bioactive forms. Inflammasomes are thought to consist of
multiple copies of an NLR that, after ligand sensing, recruit the
protease pro-caspase-1. In most inflammasomes, these proteins
are oligomerized by an adaptor protein called ASC (apoptosis-
associated speck-like protein containing a CARD). ASC consists
of both a pyrin domain and a CARD domain, which enable it to
interact with the pyrin domain of the NLR and the CARD domain
of pro-caspase-1. NLRC4 and mouse NLRP1b do not need ASC
to form an inflammasome, but when ASC is recruited, the pro-
duction of cytokines following NLRC4 signaling is much more
efficient (57–59). However, since no NLR inflammasome structure
has yet been solved (30, 60), there is still debate on the exact com-
position of inflammasomes. A “non-canonical” pathway resulting
in inflammasome function has recently been described, in which
caspase-11 activation by cytosolic Gram-negative bacteria such
as Escherichia coli and Citrobacter rodentium enhances caspase-1
inflammasome activity or instigates cell death (61–63).
HOW NLRs MIGHT SHAPE THE FIVE CATEGORIES OF
ADAPTIVE IMMUNE RESPONSES
DENDRITIC CELLS IN INNATE AND ADAPTIVE IMMUNITY
The numerous pathogens we encounter everyday do not normally
cause disease because most are quickly eliminated by our innate
immune system. Under certain circumstances, some pathogens
can evade our first line of defense and our adaptive immune sys-
tem must use alternative tactics to combat the invading pathogen.
APCs are critical for initiating this adaptive immune response by
processing antigen and presenting it to naive T cells. Among APCs,
DCs are thought to be the most potent as they temporally express
requisite T cell co-stimulatory molecules, are readily motile and are
widely distributed throughout the body forming a remarkable net-
work of sentinel cells (64, 65). Under the steady state, DCs patrol
the body seeking out evidence of invasion or malfunction. They
express a variety of PRRs, including TLRs, NLRs, RLRs, and CLRs;
PRRs are one major pathway DCs use to recognize either foreign
invaders (containing PRR-stimulating PAMPs) or self molecules
that have become altered (e.g., dying or transformed cells contain-
ing DAMPs). PRR activation dramatically impacts DC function
by altering antigen presentation, phagocytic and macropinocytic
capacity, and migratory properties. This allows DCs in peripheral
tissues to transmit information about infection or tissue damage
to the distal secondary lymphoid organs where naïve T-cells await
stimulation.
The role of TLRs in shaping adaptive immunity via modulat-
ing DC function is well-studied, while the role of NLRs in adaptive
immunity is less well understood. Recent studies suggest that the
NLRs NOD1 and NOD2 might influence T cell differentiation via
enhancing cytokine production from DCs in synergy with TLRs
(66, 67). Work from our group and others demonstrated that par-
ticular NLRs can regulate DC migration during inflammation and
infection (13, 14, 68). Antigen presentation depends critically on
CIITA and NLRC5 while inflammasome activation results in IL-1β
and IL-18 production, which can have both autocrine effects on
DC maturation as well as shape the differentiating T cell cytokine
profile (Figure 2). Despite these few examples, most of the work
on NLRs has not clearly elucidated how DCs are affected by NLR
activity. We will discuss those studies that have addressed the role
of NLRs in shaping each of the five categories of adaptive immu-
nity defined above and highlight findings regarding DCs when
known.
CATEGORY 1: ADAPTIVE IMMUNITY TO FOREIGN
PATHOGENIC TARGETS
Unlike the well-studied TLRs, which detect extracellular or endo-
somal PAMPs, the NLRs respond to pathogens that have reached
the cytosol or the accompanying cell damage caused by breaching
the cell membrane. Accordingly, NLRs can respond to particular
pathogens that might evade detection by TLRs or other PRRs. For
those NLRs that have been studied, much of the work regarding
immune consequences of NLR activity has either used in vitro
systems or evaluated the acute innate immune responses in vivo.
Therefore knowledge regarding how NLRs shape adaptive immu-
nity during infection is largely incomplete. In this section we will
discuss only those studies that addressed regulation of adaptive
immune responses to bacterial, viral, parasite, or fungal pathogens.
FIGURE 2 |The multiple roles of NLRs in dendritic cell function. Left
panel: the recognition of intracytoplasmic triggers leads to the formation of
inflammasomes and subsequent cleavage and release of the
pro-inflammatory cytokines IL-1β and IL-18 and a specific kind of cell death
called pyroptosis. Right panel: antigen presentation depends critically on
CIITA and NLRC5 while inflammasome activation results in IL-1β and IL-18
production, which can have both autocrine effects on DC function as well
as shape the differentiating T cell cytokine profile. NLRP10 and NLRP12
both are involved in DC migration from peripheral tissues to draining lymph
nodes although potentially via different mechanisms. DC, dendritic cells;
ASC, apoptosis-associated speck-like protein containing a CARD; NLR,
NOD-like receptor; CCR7, C–C chemokine receptor type 7, MHC, major
histocompatibility complex (class I left and class II right).
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BACTERIA
Nucleotide-binding oligomerization domain-containing recep-
tors are well suited to detect live cytosolic bacteria via PAMP
recognition such as flagellar proteins or the cellular effects invading
bacteria induce such as pore formation by toxins or secretion sys-
tems. The exotoxin pneumolysin (PLY) from Streptococcus pneu-
moniae is an important virulence factor responsible for forming
pores in cell membranes (69). It was previously shown that PLY
was crucial for caspase-1 activation and subsequent IL-1β and IL-
18 production during pneumococcal infections (70, 71). In line
with this, a recent study demonstrated that PLY activation of the
NLRP3 inflammasome synergized with TLR agonists on S. pneu-
moniae to enhance secretion of IL-1β, IL-1α, and TNF-α by DCs
and promote IL-17A and IFN-γ production by splenocytes (72,
73). Accordingly, NLRP3-deficient mice were more susceptible to
pneumococcal pneumonia, suggesting that the inflammasome and
its components contribute to the protective immune response to
this bacterium.
A particularly crucial NLR poised to detect intracellular
pathogens and orchestrate the subsequent adaptive immune
response is NLRC5. Although NLRC5 has been reported to have
a variety of functions in the innate immune response, its role
in transcriptional regulation of MHC class I gene expression is
essential for driving CD8+ T cell priming to intracellular bac-
teria such as Listeria monocytogenes (18). NLRC5 expression is
enhanced by PAMP as well as IFN-γ stimulation of hematopoi-
etic cells and it can move from the cytosol into the nucleus
where it binds and transactivates mouse and human class I genes
as well as associated genes such as β2 microglobulin and TAP1
(74, 75). Therefore NLRC5 has a fundamental role in antigen
presentation. The role of NLRs is less clear in another intracel-
lular bacterial infection, Mycobacterium tuberculosis (Mtb). Mtb
readily infects macrophages in vitro, which subsequently secrete
IL-1β and IL-18 in a NLRP3 inflammasome-dependent manner
(76–79). As signaling through the IL-1 receptor and MyD88 are
required for protection during Mtb infection, inflammasome reg-
ulation of protective immunity seemed likely. Using heat-killed
Mtb as part of the potent adjuvant complete Freund’s adjuvant
(CFA), Shenderov and colleagues indeed demonstrated a pro-
found impairment of Th17 differentiation in ASC- and caspase-
1-deficient mice secondary to reduced IL-1β stimulation of T
cells (80). Yet in vivo with a live infection, IL-1β levels in the
lung are unaffected by loss of ASC or caspase-1 and bacterial
burden and mortality in inflammasome-deficient mice are not
significantly different from WT mice (76, 77, 79). Although IL-1β
processing and secretion are, under most circumstances, inflam-
masome dependent, IL-1α is often secreted in an active form in
an inflammasome-independent fashion (81). As both cytokines
activate IL-1R1 and either cytokine alone is sufficient for protec-
tion during Mtb infection, it is perhaps not surprising that NLRP3
and the associated inflammasome components are dispensable for
protective immunity (82).
Although numerous studies on NLRC4 have described its role
in the innate immune response to flagellated bacteria, only a
few investigations evaluated the role of NLRC4 in generating
adaptive immunity to bacteria. Flagella from Salmonella, Yersinia,
and Pseudomonas activate the NLRC4 inflammasome in splenic
CD8α+ DCs to release IL-1β and IL-18; IL-18 can stimulate IFN-γ
production from non-cognate memory CD8+ T cells in the spleen
thereby enhancing host resistance to bacterial infection (83).
Caspase-1 regulated IL-1β and IL-18 production from DCs was
also crucial for both Th1 and Th17-dependent protective immu-
nity during Helicobacter pylori infection or even following vac-
cination, although the relevant NLR involved remains unknown
(84). Caspase-1-, ASC-, and IL-18-deficient mice are all more sus-
ceptible to infection with the intracellular bacterium Anaplasma
phagocytophilum as a result of inadequate Th1 activity. Partially via
the inflammasome-forming activity of NLRC4, enhanced IL-18
secretion (presumably by APCs in the spleen) promotes Th1 differ-
entiation and IFN-γ production – a crucial cytokine in regulating
A. phagocytophilum bacterial loads (85). In fact one evasion mech-
anism used by the pathogen Salmonella is to downregulate NLRC4
expression to prevent the inflammasome response and thereby
promote bacterial persistence and dissemination (86). Therefore
NLRC4 and its adaptors are well poised to detect intracellular bac-
teria and mount an important inflammasome-dependent IL-18
driven adaptive immune response.
VIRUSES
Toll-like receptor- and RIG-I-like receptor-mediated recognition
of viral infections results in the production of a number of viral
resistance pathways and in particular the secretion of type I
IFNs; in contrast, NLRs do not directly regulate IFNα or IFNβ
and in fact inflammasome-driven pathways can be inhibited by
these cytokines. Most NLRs do not directly recognize viral motifs
but rather respond to cell disruption induced during viral infec-
tion with inflammasome-dependent cytokine secretion (87–89).
The most extensively studied virus that activates inflammasome
pathways is the respiratory pathogen influenza. Much like the
pore forming bacteria described above, influenza can activate
the NLRP3 inflammasome via insertion of a proton-selective ion
channel, which it uses to change ionic gradients in intracellular
compartments during viral entry and propagation, but also alerts
NLRP3 to presence of the virus (90).
It is well known that IL-1 cytokines are crucial to the Th1 and
CD8+ T cell adaptive immune response to influenza; accordingly,
ASC and caspase-1 are also needed for protective adaptive immu-
nity (91, 92). A recent paper showed that DCs from elderly mice
exhibited decreased expression of ASC, NLRP3, and caspase-1
compared with DCs from infected young mice and the con-
comitant blunted IL-1β response resulted in enhanced morbidity
and mortality in influenza-infected elderly mice (93). A similar
study demonstrated that TLR3 or NLRP3 stimulating adjuvants
enhanced the efficacy of influenza virus-like particle vaccines in
aged mice (94). These studies suggest that suppressed NLRP3
inflammasome activity during aging impairs protective adaptive
immunity to influenza. Yet the course of influenza infection in
different studies using NLRP3-deficient mice widely varied with
some studies showing enhanced influenza susceptibility and oth-
ers showing no difference (92, 95, 96). It was suggested that these
opposing results might be due to different doses of influenza
virus inoculation or the different viral strains used in these stud-
ies (92), but an alternative explanation might come from recent
data on the role of IL-1 cytokines in regulating DC migration
Frontiers in Immunology | Molecular Innate Immunity December 2013 | Volume 4 | Article 486 | 4
Liu et al. How NLRs shape adaptive immunity
during influenza infection. Pang et al. found that IL-1 signaling
in pulmonary DCs was required for proper DC migration to lung
draining lymph nodes and subsequent activation of influenza spe-
cific T cells; however, DC intrinsic activation of NLRP3 was not
needed for antigen presentation or T cell priming (97). Therefore,
much like the pathways described for Mtb, if inflammasome-
independent IL-1α can be generated during infection, adaptive
immunity should be minimally impacted in the absence of NLRP3,
ASC, or caspase-1.
West Nile virus (WNV) is an emerging flavivirus capable of
infecting the central nervous system (CNS) and mediating neu-
ronal cell death. A recent study demonstrated that acute WNV
infection induced IL-1β production in vivo, and that IL-1-R-,
caspase-1-, and NLRP3-deficient mice exhibited increased suscep-
tibility to WNV (98). This outcome was associated with increased
accumulation of virus within the CNS and reduced anti-viral
activity of effector CD8+ T cells. This study indicates that IL-
1β signaling and the NLRP3 inflammasome are important for
host control of virus replication in neurons and WNV-induced
pathology in the CNS.
PARASITES
Although the NLRP3 inflammasome is activated during many
parasitic infections (e.g., Leishmania major) or by byproducts of
parasitic infections (e.g., malarial hemozoin) and its effect on the
acute innate immune response is well documented, the role of
NLRP3 or other NLRs in the adaptive immune response to par-
asites has not been extensively studied (99, 100). The role of the
NLRP3 inflammasome in shaping the T cell response to Schisto-
soma mansoni has been studied (101); the authors found that both
ASC- and NLRP3-deficient mice failed to upregulate IL-1β in the
liver and all parasite-specific helper T cell responses (Th1, Th2, and
Th17) were reduced after infection compared to wild type con-
trols. Surprisingly, these impaired T cell responses were correlated
with smaller liver granulomas and attenuated immunopathology
in the inflammasome-deficient mice, suggesting enhanced adap-
tive immunity to Schistosoma by NLR activation is not necessarily
beneficial to the host.
FUNGI
It has been reported that Candida albicans hyphae activate NLRP3
(102, 103) and NLRP3-deficient mice succumb to both dissem-
inated Candidiasis (102, 104) and mucosal Candidiasis (103),
suggesting that the inflammasome is crucial for anti-fungal host
defense. Caspase-1- and ASC-deficient mice indeed have impaired
Th1 and Th17 responses during Candida albicans, leading to
increased fungal outgrowth and reduced survival (105). Further,
exogenous IL-18 was able to restore Th1 immunity to Candida
in caspase-1-deficient mice (106), indicating that inflammasome-
derived cytokines direct protective adaptive immune responses
during invasive fungal infection.
NLRP10 has a critical role in DC localization in vivo; in its
absence, impaired DC migration results in a profound helper T
cell priming defect in a number of immunization models (14). In
line with this, NLRP10-deficient mice have increased susceptibil-
ity to disseminated Candidiasis, as indicated by decreased survival
and increased fungal burdens, secondary to impaired induction
of Candida-specific Th1 and Th17 responses (68). In fact, adop-
tive transfer of Candida-specific primed T cells from WT mice
rescues NLRP10-deficient mice infected with Candida. Therefore
NLRP10, by regulating the movement of DCs presumably in the
spleen in this case, can dramatically regulate pathogen-specific
adaptive immunity. It still remains to be determined how NLRP10
activity is triggered during Candida infection and the molecular
function of NLRP10 that regulates DC migration.
CLINICALLY APPROVED VACCINE ADJUVANTS
The development of vaccines against infectious pathogens has
been and continues to be one of the most important medical
interventions in global health. Many of our current vaccines
do not induce adequate immunity unless co-administered with
an adjuvant, which helps initiate adaptive immunity by stim-
ulating the innate immune system. Although many pathogen-
derived adjuvants used in animal models (e.g., CFA containing
heat-killed mycobacteria or immunostimulatory oligodeoxynu-
cleotides containing CpG motifs) have the capacity to stimulate
various TLRs and NLRs, almost all clinically approved adjuvants
for human use in fact do not contain any pathogen-derived motifs.
Instead the most commonly employed adjuvants in human vac-
cines are aluminum hydroxide, which is a crystalline mixture
and MF59, which is an oil-in-water emulsion. We and a num-
ber of other groups hypothesized that these adjuvants might
trigger a DAMP-dependent rather than PAMP-dependent innate
immune response thereby accounting for their immunostimu-
latory properties. Indeed alum is a potent activator, like many
other insoluble crystals, of the NLRP3 inflammasome (107–111);
however, whether triggering this innate immune pathway subse-
quently instructs the adaptive immune response during vaccina-
tion remains unclear (112). Different groups using the same mice
with similar models have observed opposing phenotypes, possi-
bly suggesting that multiple factors influence whether NLRP3 is
relevant to the adjuvant function of alum. Some studies, includ-
ing our own, have suggested that induction of adaptive immunity
following alum-based vaccination requires a functional NRLP3
inflammasome via maturation of DCs (107, 109, 110); however,
other groups found that NLRP3-deficient mice had intact T and
B cell responses following vaccination with alum and antigen
(108, 111, 113). Further, numerous other pathways downstream
of alum immunization have now been proposed to be required for
its adjuvant function, including DNA released during cell death,
lysosomal permeabilization resulting in cathepsin B and S release,
extracellular ATP, and uric acid release (114–117). Surprisingly, all
of the above stimuli have also been directly implicated in NLRP3
inflammasome activation, yet in all cases NLRP3 was not required
for successful immunization, leaving us without consensus on the
mechanism by which alum regulates adaptive immunity. As alum
has proven to be a great adjuvant for almost 100 years in that it
works in most people, it is likely that it has multiple routes to
induce immunity. In isolated systems used by different groups
using murine models we have uncovered some, but perhaps not
all, of those mechanisms.
A similar story has emerged for the oil-in-water adjuvant MF59
(118, 119). Ellebedy et al. showed that although NLRP3 is dis-
pensable for the adjuvant effect of MF59, ASC is crucial for
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the induction of antigen-specific IgG following vaccination with
H5N1 in combination with MF59 (118). Indeed, activation of both
germinal center B cells and CD4+ T cells are significantly reduced
in ASC-deficient mice, but not in NLRP3- or caspase-1-deficient
mice. As it has been shown that DCs take up both antigen and
MF59 and transport them to draining lymph nodes (120, 121), the
markedly reduced secretion of inflammatory cytokines by ASC-
deficient DCs upon stimulation with MF59 may be responsible for
impaired T and B cell responses (118). Consistent with these find-
ings, Seubert et al. also demonstrated that NLRP3 is not required
for induction of adaptive immune responses to Neisseria meningi-
tides with three particulate adjuvants: alum, MF59, and CFA (119).
Apart from traditional adjuvants, nanoparticles have been
extensively studied as vehicles to co-deliver antigens and adju-
vants for effective vaccination (122). Using a biocompatible poly-
ester, poly(lactic-co-glycolic acid) (PLGA), loaded with antigen
Demento et al. demonstrated that LPS-modified particles are
preferentially internalized by DCs compared to uncoated nanopar-
ticles and elicit NLRP3 inflammasome activity (123). Further, inhi-
bition of endocytosis and lysosomal destabilization diminished
inflammasome activity, suggesting that the rupture of lysosomal
compartments by nanoparticles is a crucial trigger for inflamma-
some activation (123, 124). A more recent study found that porous
silicon nanoparticles enhance phagocytosis and subsequent acti-
vation of DCs as well as IL-1β production (125). Administration
of these nanoparticles also enhances DC migration to draining
lymph nodes and T cell priming. However, adaptive immunity
was either not evaluated in these studies or only partially affected
in the absence of NLRP3, again leaving us with a vaccine formula-
tion that can activate the inflammasome but might not absolutely
require its activity for the initiation of adaptive immunity.
Nucleotide-binding oligomerization domain-containing recep-
tors not only perform a major role in innate immune responses,
but also have defined roles in generating effective adaptive immune
responses against various infections. However, a number of impor-
tant questions remain unanswered, including the mechanism by
which NLRs detect molecules of microbial origin as well as how
NLRs cooperate with other PRRs to mount an effective immune
response against pathogens. It is possible that some NLRs serve
as direct receptors of PAMPs, while others instead detect the
perturbation of the host microenvironment by pathogens (42).
Undoubtedly, understanding how NLRs recognize microbial prod-
ucts and initiate subsequent adaptive immune responses will pro-
vide new insights into vaccine design and vaccination strategies
against infectious diseases.
CATEGORY 2: ADAPTIVE IMMUNITY TO FOREIGN
NON-PATHOGENIC TARGETS
The diversity of molecules that can act as allergens is immense
with the only unifying theme being the allergic type 2 immune
response induced; in most cases this immune response is driven
by Th2 lymphocytes [for review, see (126)]. Allergens are for-
eign, non-self molecules, and as such could trigger innate immune
responses. Yet as most [but not all (126)] of these molecules are
considered inherently non-pathogenic, it is unclear if they trig-
ger classic PRR pathways. Many allergens indeed have enzymatic
activity or are pathogen-derived (e.g., helminths) or can mimic
PAMPs (e.g., Derp 2) and this might be how the innate immune
system is tricked into initiating adaptive immunity (127, 128). Are
NLRs involved in sensing allergens as pathogenic and determining
the subsequent maladaptive immune response? Given that some
allergens can directly induce tissue damage along with previous
implications of IL-1 and IL-33 in Th2-mediated inflammatory
responses, the prediction that NLRs play a role in the develop-
ment of allergic diseases seems obvious. However, the evidence in
favor of this argument is limited (129).
IL-33 is a prime candidate in the development of allergy as it
clearly promotes Th2 (as well as ILC2) responses (130–133). Early
work in the inflammasome field suggested that IL-33 was cleaved
by caspase-1 and so this cytokine was grouped with the other
inflammasome-regulated cytokines IL-1β and IL-18 and further
postulated to be one mechanism by which inflammasome activ-
ity could regulate Th2 development (107). However, more recent
work indicates that active IL-33 is in fact released from necrotic
cells and functions more like a DAMP; if IL-33 is instead cleaved
by caspase-1 or by caspase-3 during apoptosis it becomes inactive
and fails to bind its receptor T1/ST2 (134–136). Therefore, the
data supporting a role for IL-33 in the development of Th2-driven
allergic inflammation indicates that this cytokine can function like
a DAMP and shape the immune response but does not implicate
a role for inflammasome activity in such a process.
LUNG
Similar to the diversity of antigens that can serve as allergens,
there is a spectrum in the pathophysiology of the major aller-
gic lung disease, asthma. The classic form is triggered by inhaled
allergens that trigger degranulation of mast cells and basophils
in the lung in an IgE-dependent manner and results in airway
constriction and mucus production along with tissue inflamma-
tion dominated by activated eosinophils. Although the IL-1 gene
cluster on chromosome 2 and promoter polymorphisms in IL-18
have been weakly associated with susceptibility to asthma (137,
138), the mechanistic link between IL-1, inflammasome activity
and Th2 induction is uncertain partly due to the range of allergic
airway disease models employed. As many murine allergy models
involve intraperitoneal administration of antigen with the potent
adjuvant aluminum hydroxide, the role of NLRs during the T cell
sensitization phase to allergens in lung draining lymph nodes is dif-
ficult to determine (139); indeed intraperitoneal injection models
have demonstrated a range of effects in IL-1- or IL-1 receptor-
deficient or inflammasome-deficient mice (113, 140, 141). In
contrast, when inhalational allergens are administered with nitro-
gen dioxide, urban particulate matter, or with presumed low-level
PAMP contamination, a more significant role for IL-1 pathways
and inflammasome molecules has been observed in some (142–
145) but not all allergic airway disease models (113, 141). One
caveat to these latter systems however, is that they can have a sig-
nificant Th17-driven inflammatory response and as some studies
have demonstrated a significant role for inflammasome-derived
IL-1β on Th17 but not Th2 induction, the observed differences in
inflammation might be due to loss of the Th17 component (143,
146). Nevertheless, inflammasome activity likely via IL-1 secretion
appears to modulate particular aspects of adaptive immunity to
inhaled triggers.
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GASTROINTESTINAL
The disease corollary of this type of allergic adaptive immune
response in the gastrointestinal system is food allergies. Outside
of one study on subjects with a specific clinical subset of food
allergies demonstrating an association with Nlrp3 polymorphisms
(147), there has been no link yet established between NLRs and
the development of adaptive immunity to food antigens.
SKIN
The other primary organ affected by allergic adaptive immunity
is the skin. Disorders such as atopic dermatitis (in some cases
referred to as eczema) and allergic contact dermatitis (included
under contact hypersensitivity) are manifestations of an often
Th1/Th2 mixed adaptive immune response to unclear targets,
but can include prototypical allergens such as house dust mite
antigens or small molecule contact allergens. Accordingly, the
inflammasome-dependent cytokines IL-1β and IL-18 have been
implicated in promoting aspects of both a Th2 (elevated IgE, mast
cell, and basophil degranulation with overproduction of type 2
cytokines) and a Th2- and IgE-independent innate inflammatory
response (basophil and mast cell degranulation) (148, 149). IL-18,
traditionally thought of as a Th1-promoting cytokine, has been
implicated in the development of atopic dermatitis; transgenic
mice expressing either human caspase-1 or IL-18 in keratinocytes
develop spontaneous atopic dermatitis-like lesions with elevated
mast cell activity (148). House dust mite cysteine proteases can
directly activate the NLRP3 inflammasome in keratinocytes, which
has been one proposed mechanism for induction of caspase-
1 activity (150); however, mast cell chymase can also directly
cleave pro-IL-18 independently of caspase-1 (151). Further work
is needed to clarify if particular NLRs are indeed needed to direct
the adaptive immune response to skin antigens in atopic dermati-
tis, but clearly pathways downstream of particular NLRs appear
relevant.
Contact hypersensitivity is triggered by contact allergens (hap-
tens, most often small lipophilic molecules that bind to self
proteins) that induce a Th1/CD8+ T cell driven neutrophilic
inflammation. An important role for IL-1β in the development of
contact hypersensitivity has been known for many years (152) and
a role for inflammasome-forming NLRs seems likely, especially
given the expression of many NLRs and associated inflammasome
components in the skin (153). Multiple studies have suggested
that IL-1β directly enhances Langerhans cell activity in priming
T cells to contact allergens (154, 155). However, subsequent work
on this unique cell has indicated that it is primarily derived from
embryonic fetal liver monocytes and locally maintained in contrast
with classical DCs; further, Langerhans cells migrate significantly
slower (e.g., on the order of 3–4 days) to draining LNs than typical
DCs (156, 157). Recent studies instead suggested a regulatory role
of Langerhans cells to skin-derived antigens (157). Therefore, the
exact role of Langerhans cells in initiating adaptive immunity to
contact sensitizers is not clear. Yet separate studies using caspase-
1, ASC, or NLRP3-deficient mice all support a requirement for
inflammasome activity in the generation of immunity to skin
sensitizers (153, 155, 158, 159). This implies that inflammasome-
regulated IL-1β might target cells other than Langerhans cells
during sensitization in the skin such as dermal DCs; alternatively,
inflammasome-dependent signals beyond IL-1β might directly
modulate the lymphocyte response to contact sensitizers.
Beyond regulating inflammasome-induced cytokine secretion,
NLRs can play a more direct role in regulating sensitization of
T cells via affecting DC maturity and migration. Recently two
NLRs were described to regulate the movement of DCs in an
inflammasome-independent manner and gene knockouts of each
had dramatic but specialized effects on allergic models in vivo.
Arthur et al. demonstrated that hapten-induced contact hyper-
sensitivity was defective in the absence of inflammasome-forming
NLRP12 potentially via regulation of DC and neutrophil motility
but independent of inflammasome activity (13). However, subse-
quent work from the same group indicated that NLRP12-deficient
mice had no defect in T cell sensitization to antigens inhaled
or administered intraperitoneally in two different allergic air-
way disease models (141), suggesting that NLRP12-dependent DC
migration might be specific to skin DCs. NLRP10 was described by
a number of groups including our own to regulate DC-dependent
T cell priming as well as NOD1 signaling and inflammasome
activity [please see (160) for review]. Our work suggests that sen-
sitization to inhaled or subcutaneous antigens is defective in the
absence of NLRP10 secondary to a DC migration defect; however
T cell priming following topical sensitization was not evaluated
(14). Therefore whether the NLRP10 and NLRP12 phenotype
are complementary versus overlapping has yet to be determined.
But interestingly both NLRP10 and NLRP12 were identified as
susceptibility loci from GWAS studies of patients with atopic der-
matitis (161, 162). NLRP10 is most highly expressed in the skin
and knockdown of human NLRP10 in primary dermal fibroblasts
attenuates innate immunity mediated by NOD1 (163). Therefore,
further work is necessary to clarify if NLRP10 regulates adaptive
immunity to skin antigens via hematopoietic cellular changes or
rather acts in the barrier function of the skin.
CATEGORY 3: ADAPTIVE IMMUNITY TO SELF TARGETS
Autoimmunity is a pathologic process wherein T and B lympho-
cytes are activated by self molecules and induce damage to host
tissues. As tolerance is built into the education of T and B cells,
an active process must overcome tolerance to induce lymphocyte
sensitization to self molecules; the innate immune system plays
one key role in that process. Much of the early work on NLRs
and inflammasomes followed the discovery that constitutively
active mutants of NLRP3 were responsible for a subset of peri-
odic fever syndromes now grouped under the term autoinflam-
matory diseases [for review, see (164)]. This NLRP3-dependent
collection of rare syndromes, called the Cryopyrin-associated peri-
odic syndromes (CAPS), is characterized by self-limited bouts of
inflammation of the joints and skin with more systemic inflam-
mation depending on the subtype; all are accompanied by fever
and elevated levels of IL-1β (165). In fact, these disorders are now
successfully treated by blocking IL-1β activity (166). It is impor-
tant to recognize that these disorders do not include self-reactive
T or B cells and therefore are distinct from autoimmune diseases
(167). Although both autoinflammatory and autoimmune dis-
eases involve recurrent episodes of inflammation (sometime with
similar cytokine profiles) triggered by self molecules, the cells that
drive inflammation and the nature by which they do so in the
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two disease categories are different. Therefore for the remainder
of this section, we will only consider the role of NLRs in the
adaptive immune response to self targets and therefore autoim-
mune diseases. In contrast to the clear mechanistic link between
autoinflammatory diseases and NLR activity, the link between
autoimmunity and NLR activity is more tenuous (168).
How would NLR activity drive autoimmunity? One obvious
link between inflammasome-forming NLRs and adaptive immu-
nity is the potent cytokine IL-1β. IL-1β enhances expansion and
survival of T cells (169), promotes differentiation of potentially
pathogenic Th17 cells (170, 171) and can promote APC migra-
tion, thereby potentially enhancing antigen presentation (97)
(Figure 2). Yet IL-1β cannot be sufficient for driving autoimmu-
nity as autoreactive T and B cells are not a part of the patho-
physiology of autoinflammatory diseases (165, 167). Indeed there
is only limited evidence that NLR triggering induces a complete
DC maturation program the way TLR activation transforms naïve
DCs into potent APCs. Yet as discussed previously, particular NLRs
such as CIITA, NLRC5, NLRP10, and NLRP12 regulate key steps
in the antigen presenting function of DCs (34) and might regulate
adaptive immunity to self in this way.
MULTIPLE SCLEROSIS
Perhaps the strongest link between an inflammasome-forming
NLR and an autoimmune process is the link between NLRP3 and
multiple sclerosis (MS). MS is a Th1 and Th17-driven response
directed against myelin-producing oligodendrocytes in the CNS
(172). Overexpression of IL-1β, IL-18, and caspase-1 has long been
recognized in samples from MS patients (173–175). Studies in
animal models further strengthened a connection between inflam-
masome activity and MS. A murine model with a clinical pheno-
type similar to MS, experimental autoimmune encephalomyelitis
(EAE) exists. However this model relies on a highly artificial
induction step to induce CNS-reactive T cell priming using CFA
administered with peptides from the CNS (14). As Mycobacterium
can activate multiple NLRs including NOD1, NOD2, and NLRP3
(66, 80, 176), one might expect to observe differences in adaptive
immune-mediated disease when the adjuvant contains Mycobac-
terium as does CFA. Despite bypassing the natural immunization
process, this animal model has been useful to dissect the immune
pathways governing the autoimmune destruction of the CNS.
Indeed caspase-1-deficient mice have reduced disease severity and
delayed onset of paralysis (177). Further, caspase-1 dependent IL-
1β and IL-18 from activated DCs promotes Th17 and γδ T-cell
activation directed against the CNS (178, 179).
Once the link between caspase-1 and NLRP3 was identified, an
obvious question was whether this particular NLR regulates the
adaptive immune response to the CNS. Yet the answer remains
ambiguous. One group using two different models of EAE found
that NLRP3-deficient mice had normal CD4+ T cell activation
to CNS antigens but poor Th17 and Th1 differentiation. This
was accompanied by reduced adaptive immune cell infiltration
of the CNS and improved clinical outcomes (180, 181). Con-
sistent with this finding, another group subsequently reported
that NLRP3-sufficient DCs were required in order to program
the primed autoreactive CD4+ T cells to traffic into the CNS
(182). In contrast to the above work, a third group demonstrated,
using a similar EAE model that NLRP3 deficiency did not affect
the development of paralysis and presumably retained autore-
active T cell activity (183). Instead this latter study proposed
an inflammasome-independent role for the adaptor ASC in the
autoimmune disease process; however, subsequent work from this
group demonstrated a second mutation in their strain of ASC-
deficient mice in the guanine nucleotide-exchange factor Dock2,
which regulates actin polymerization during lymphocyte migra-
tion and DC antigen uptake (184). Therefore, the findings from
the 2010 paper might be affected by a non-inflammasome related
mutation in the ASC-deficient mice used. Nevertheless, the find-
ings in NLRP3-deficient mice should have been unaffected and
therefore still suggest NLRP3-independent induction of adaptive
immunity in EAE. To date, no clear mechanism explains the dis-
crepancy in results between groups using NLRP3-deficient mice;
however, a recent paper by Inoue et al. suggests that the dose of
Mycobacterium used in the CFA adjuvant determines whether a
NLRP3-dependent or -independent response is observed in EAE
models (185). Since, in all of the papers discussed above the dose
of Mycobacterium used was not specified, it remains unclear if
a difference in mycobacterial doses explains the above discrep-
ancy. Therefore the question remains whether an inflammasome-
dependent step is required to initiate adaptive immunity to CNS
self antigens.
We recently described another NLR crucial in the early stages
of T cell priming against self-molecules in the CNS in a non-
inflammasome-dependent manner. NLRP10 regulates the move-
ment of antigen-laden DCs and in a standard EAE model, NLRP10
deficiency almost completely abrogated the priming of IL-17 and
IFN-γ producing CD4+ T cells to CNS peptides and the associ-
ated demyelination (14). In this case, IL-1β and IL-18 production
were not altered but rather autoreactive T cells were not activated
because the crucial step of antigen presentation in secondary lym-
phoid organs failed. Again, given the use of CFA in this model,
one can only conclude that DC movement and T cell priming are
NLRP10-dependent in MS if the immune system is triggered in an
analogous way during the natural course of disease.
DIABETES
In contrast to MS/EAE, no other autoimmune disease has been
as clearly linked to the activity of an NLR. Type 1 diabetes (T1D)
is driven by T cells specific for beta cells in the pancreas ulti-
mately resulting in destruction of the islets and is accompanied by
systemic production of islet-specific antibodies. Although there
is mounting evidence that NLRP3 inflammasome activity pro-
motes insulin resistance in models of type 2 diabetes (T2D)
(186–188), there is scarce evidence indicating that the same is true
for autoimmune T1D. In fact, the unaltered development of spon-
taneous diabetes in NOD mice lacking caspase-1 argues against
a role for inflammasome activity in the pathogenesis of autoim-
mune diabetes (189). Yet various human studies have suggested
that particular polymorphisms in NLRP1 and NLRP3 confer risk
for T1D (190, 191). Further, IL-1β is known to promote beta
cell secretory dysfunction and apoptosis and this has prompted
clinical trials of IL-1 blockade in both T1D and T2D. Unfor-
tunately though, this approach was shown to be ineffective in
new onset type 1 diabetics in a recent multicenter randomized
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double-blind placebo-controlled trial (192). Older work using the
mouse NOD model suggested that IL-1R blockade in fact does not
alter insulitis or the autoimmune process, although glycemic con-
trol was improved (193). Therefore, inflammasome activity and
IL-1β in particular might play a more significant role in insulin
sensitivity and beta cell dysfunction (T2D) rather than regulating
autoimmunity to beta cells (T1D).
RHEUMATOID ARTHRITIS
The pathology in rheumatoid arthritis (RA) is driven by a T-
cell-mediated immune response directed at the synovial lining of
the joints and is accompanied by autoreactive antibodies system-
ically. Unlike some of the other autoimmune diseases discussed
above, IL-1β plays a less significant role in the pathology of RA
(194) and therefore the role of NLRs and inflammasomes in dri-
ving the autoimmune process has been less extensively studied.
A handful of studies specifically looking for polymorphisms in
NLRs or associated inflammasome components has indeed found
some associations with NLRP1 and NLRP3 polymorphisms and
RA susceptibility (195, 196). Yet two groups using two different
mouse models of antigen-induced arthritis reported that the adap-
tive immune response directed at the joints was NLRP3, NLRC4,
and caspase-1 independent (197, 198). Interestingly, both reported
dependence instead on the inflammasome adaptor ASC. But as
described above, one of these groups subsequently discovered
an unintended mutation in a non-inflammasome pathway in the
ASC-deficient mice relevant for antigen presentation by DCs and
T cell activation (184). Given that both groups observed T cell
and DC intrinsic defects in their strain of ASC-deficient mice,
it is again possible that the above finding stems from an ASC-
independent defect. Yet other data from these papers suggests that
NLRP3, NLRC4, and caspase-1 do not appear to play a significant
role in the adaptive immune response in RA models.
LUPUS
Systemic lupus erythematous (SLE or lupus) affects a wide range of
organs primarily driven by immune complexes of nuclear antigens
bound by autoantibodies, which initiate inflammation and tissue
destruction. The primary nuclear antigen, double stranded DNA
(dsDNA) can potentially act as a DAMP to trigger many PRRs
including TLR7 and TLR9 (199), NLRP3 (200), and AIM2 (201)
and each of these receptors has been implicated in the pathogenesis
of lupus. In the case of the latter two PRRs, inflammasome func-
tion has been suggested from older studies demonstrating a crucial
role for IL-1β (but not IL-1α) in the development of anti-nuclear
antibodies and lupus disease manifestations (202). Indeed a recent
elegant study by Shin et al. identified how NLRP3 is triggered by
dsDNA; human monocytes produce IL-1β only when stimulated
with dsDNA in combination with anti-dsDNA antibodies, the
complexes known to trigger inflammation in lupus (200). Further,
supernatants from these stimulated monocytes promoted IL-17
production from memory CD4+ T cells. This suggests that the
complexes formed in lupus patients can activate myeloid cells via
NLRP3 and thereby reinforce T cell activation. It remains unclear
though if this process and the NLRP3 inflammasome are required
for initiation of the self-directed adaptive immune process. In fact
a recent limited genetic analysis of Nlrp3 (and Aim2) failed to
find an association of particular single nucleotide polymorphisms
(SNPs) with SLE predisposition; instead, polymorphisms in Nlrp1,
including one in the promoter region, were associated with SLE in
a Brazilian population (203).
Interestingly, non-synonymous coding-region and promoter
polymorphisms in Nlrp1 have been recurrently identified in
genetic screens for a number of autoimmune diseases including
vitiligo (melanocytes in the skin and hair targeted), Addison’s dis-
ease (cortex of the adrenal gland targeted), type 1 diabetes (beta
cells in the pancreas targeted), systemic sclerosis (nuclear antigens
targeted), RA (synovium in joints targeted), and SLE (nuclear anti-
gens targeted) (190, 191, 195, 203–206). Frustratingly, there has
been little work done to identify how these various polymorphisms
influence autoimmunity susceptibility outside of a possible effect
on transcription level of Nlrp1 (195). Indeed little is known about
the function of NLRP1 in vivo, in part due to the divergence of
Nlrp1 genes between humans and mice. But of all NLRs discussed,
NLRP1 is the most widely implicated in susceptibility to autoim-
munity in human studies. Until a mechanistic understanding of
these SNPs is discovered, the association with autoimmunity does
not provide a paradigm in which to develop a role for NLRP1 in
the initiation of adaptive immune processes directed against self
molecules.
CATEGORY 4: ADAPTIVE IMMUNITY TO ALTERED SELF
TARGETS
As tumors are derived from host cells that have lost the ability
to regulate their appropriate growth, there is little to mark them
as foreign or dangerous to the immune system. Outside of the
aberrant loss of particular inhibitory signals to immune cells or
altered forms of a self molecule, one signal that might alert the
innate immune system to the loss of homeostasis is excessive
cell turnover and damage to surrounding tissue, leading to the
release of DAMPs. Therefore NLRs might be a relevant pathway to
detect unchecked proliferation in tumors and initiate an immune
response to these altered host-derived cells. However, several stud-
ies have suggested that IL-1β may have a role instead in promoting
tumorigenesis (207, 208), since reducing or eliminating IL-1β can
prevent tumor metastases and progression (209, 210), thus sug-
gesting that inflammasome signaling may play a more complex
role in the tumor-immune system interaction.
COLON
Most studies of NLR function in tumorigenesis have focused on
colonic inflammation and tumor models. NLRs are involved in
the maintenance of gut homeostasis and dysregulation of this
fine-tuned balance can lead to chronic inflammation (please see
Category 5: Adaptive Immunity to Foreign Self Targets), which is
believed to create a tumor-promoting condition for intestinal can-
cer. Accordingly, mice deficient in caspase-1,ASC, NLRP3, NLRP6,
NLRP12, and NLRC4 all have increased colitis and subsequent
development of colorectal cancers in gut irritant models. In most
of these studies caspase-1 processed IL-18 is a key regulator of
these processes (211–214). Although most of these chronic mod-
els did not evaluate potential alterations in anti-tumor adaptive
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immunity, one study showed that in the absence of NLRP3 and
caspase-1, reduced IL-18 in a colorectal tumor model led to dimin-
ished IFN-γ levels in the colon (214). However, the cellular origin
of this IFN-γ was not identified and therefore it remains unclear
if anti-tumor adaptive immunity was in fact altered. In contrast,
IL-18 has been implicated in promoting tumor metastasis from
the lung, but in a T-cell and B-cell independent fashion; tumor-
derived IL-18 promoted increased expression of the inhibitory
receptor PD-1 on NK cells and prevented effective immunosur-
veillance (215). Therefore there might be a very different effect
of inflammasome activity outside of the gut, wherein secreted
IL-1β and IL-18 actually suppress tumor surveillance by innate
cells but perhaps ultimately promote adaptive immunity to tumor
antigens.
TUMOR VACCINES
Chemotherapy is one of the most commonly used treatments for
cancer patients. It has been proposed that chemotherapy works
via eliminating immunosuppressive cells and by directly inducing
tumor-cell death (216, 217). Ghiringhelli et al. demonstrated that
chemotherapy-treated dying tumor cells can activate the NLRP3
inflammasome in DCs and that a functional NLRP3 inflamma-
some in DCs is required for tumor-specific CD8+ T cell priming
(217). In this study, the authors found that NLRP3- and caspase-1-
deficient mice are unable to prime CD8+ T cells, unless exogenous
IL-1β is provided. Furthermore, they found that HMGB1 from
dying tumor cells is critical for IL-1β release by DCs. In contrast,
van Deventer et al. found that NLRP3 activity actually impairs
anti-tumor DC-based vaccination by enhancing the accumulation
of tumor-associated myeloid-derived suppressor cells (MDSC)
thereby inhibiting the cytotoxic T cell response (218). Tu et al.
also found enhanced MDSCs in gastric tumors induced by over-
expression of IL-1β in the stomach; however, the enhanced tumor
development was independent of T and B lymphocyte responses
(219). In line with these studies, Bruchard et al. demonstrated that
although chemotherapy depleted MDSCs and increased the sur-
vival of tumor-bearing mice by generating tumor-specific CD8+
T cells, it triggered the release of cathepsin B from MDSCs leading
to IL-1β secretion (220). IL-1β promoted IL-17 production from
CD4+ T cells, which in turn attenuated the anti-tumor effect of
chemotherapy via an IL-17-dependent proangiogenic effect (220).
These conflicting results may be due to the ability of particular
drugs to induce immunogenic tumor-cell death (221) or differ-
ences in the form of tumor antigens used in these studies, [i.e.,
particulate (217) versus soluble (218)], which might be taken up
by different DC subsets or recognized differently by the innate
immune system.
Although TLR ligands have been tried as adjuvants to enhance
vaccination efficiency for many years, very limited work has been
done with NLR ligands. In a recent study, Garaude et al. demon-
strated that introducing the bacterial protein flagellin, which acti-
vates TLR5, NAIP5, and NLRC4, into tumor-cell lines induced
a potent CD8+ T cell anti-tumor adaptive immune response
and thereby helped eliminate injected tumors. They additionally
found that priming of tumor-specific CD4+ and CD8+ T cells by
DCs was promoted by the dual triggering of TLR5 and NLRC4
(222). Therefore, under specific situations, NLR triggering, possi-
bly in combination with other PRRs, crucially regulates adaptive
immunity to altered host cells in tumors.
CATEGORY 5: ADAPTIVE IMMUNITY TO FOREIGN SELF
TARGETS
Up to 100 trillion microbes inhabit the human intestinal tract,
which is 10-fold the number of human cells in the body. This
ecosystem consists of fungi, bacteria, archaea, and viruses; most
of these organisms are not pathogenic, but rather commensal,
meaning that both the host and the organism benefit from co-
habitation. Since these organisms function as a part of the human
body and the immune system tolerates their presence, they can
be thought of as an immune target that is both foreign but also
self. A majority of these microbes can be found in the colon,
where they contribute to the energy we extract from food, defend
the mucosa against invading pathogens, induce the production
of protective mucus and antimicrobial peptides as well as influ-
ence host immunity (223, 224). The microbiota is needed to
adequately develop gut-associated lymphoid tissues by recruit-
ing IgA-producing plasma cells and CD4+ T cells to the lamina
propria and directing the development both of local lymphocyte
subsets (224–226) including Th17 and Treg populations, as well
as distal B cell and T cell zones in lymph nodes and the spleen
(227). Accordingly, changes in the microbiota are believed to con-
tribute to the development of intestinal diseases as well as systemic
metabolic disorders.
To date NLRs, which are clearly present and highly active in the
gut, have not been implicated in educating these intestinal lym-
phocyte populations. However, their activity can have a profound
impact on the composition of the microbiota and loss of NLRs
with the ensuing dysbiosis can impact both local and systemic
immunity (12, 227). The gut immune system must be able to tol-
erate commensal microbes, while still being able to keep microbes
from coming in close proximity to the epithelial cell layer and
inducing damage; the ability of NLRs to identify pathogens that
have breached cell membranes makes them well suited to act at
this level of barrier function (Figure 1). Several examples have
been described: decreased NLRP3 expression and defective NOD2
have been associated with Crohn’s disease, in which the micro-
biota is believed to contribute to the intestinal inflammation (10,
228, 229); NLRP3 and NLRP6 deficiency lead to a high suscep-
tibility to dextran sodium sulfate (DSS)-induced colitis (54, 230)
and NLRP6 was shown to impact the composition of the micro-
biota leading to an intestinal dysbiosis that resulted in spontaneous
intestinal inflammation (54). Huber et al. found an important role
for NLRP3 and NLRP6 in regulating tissue repair and tumorige-
nesis in the colon through IL-18-dependent downregulation of
dendritic cell-derived IL-22 binding protein (231). Conversely,
inflammasome regulation of adaptive immunity at distal sites can
be influenced by the gut microbiota. Ichinohe et al. demonstrated
that commensal bacteria were critical for the induction of adap-
tive immune responses (including CD4+ T cell, CD8+ T cell, and
antibody responses) to respiratory influenza infection by provid-
ing “signal 1” or the priming signal for inflammasome substrates
pro-IL-1β and pro-IL-18 (232).
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However, the impact of NLRs on the induction of adaptive
immune responses in the intestine needs further elucidation. We
have previously proposed a “two-hit model” of PRR triggering to
set thresholds for adaptive immunity in which DCs are primed by
TLR activation but licensed by NLR activation (34). This model
could also work to maintain homeostasis in the gut, in which
the presence of microorganisms could lead to activation of TLRs,
but activation of NLRs by DAMPS would be the decisive step in
initiating an adaptive immune response.
CONCLUSION
Although a tremendous amount of work has been done resulting
in significant advances regarding our understanding of NLR func-
tion over the past decade, there remains limited evidence that NLRs
directly regulate adaptive immune responses. In ways distinct
from TLR-driven pathways, NLRs indeed regulate aspects of DC
migration, antigen presentation, and production of particular pro-
inflammatory cytokines that can shape developing T cell responses
(Figure 2). We have previously argued that this potentially rep-
resents a division of labor between two of the major subsets of
PRRs, the TLRs and NLRs (34), although some NLRs can insti-
gate inflammatory processes that overlap or modulate TLR-driven
pathways to impact adaptive immunity. Yet for a majority of NLRs,
including those identified through unbiased genetic screens such
as NLRP1 (see Category 3: Adaptive Immunity to Self Targets),
we do not know how these innate immune molecules function to
instruct immunity. Given the location of these molecules and the
distinct set of insults that stimulate their activity, it is not surpris-
ing that they have thus far been found to fulfill specialized but
delimited functions in the intricate interplay between the innate
and adaptive branches of the immune system.
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